Franklin Street Advisors Inc. NC Invests in Axsome Therapeutics

The institutional investor acquired 10,000 shares of the pharmaceutical company's stock.

Apr. 9, 2026 at 8:24am

A high-contrast, black and white close-up image of complex banking machinery and financial infrastructure, conveying the impersonal power of institutional finance as a metaphor for the investment in a pharmaceutical company.An institutional investor's new position in a pharmaceutical company reflects growing confidence in the firm's central nervous system drug pipeline.Franklin Today

Franklin Street Advisors Inc. NC, an institutional investor, acquired a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the fourth quarter. The firm purchased 10,000 shares of the company's stock, valued at approximately $1,826,000.

Why it matters

Axsome Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The investment by Franklin Street Advisors Inc. NC suggests institutional confidence in the company's pipeline and future growth potential.

The details

According to a disclosure with the Securities and Exchange Commission, Franklin Street Advisors Inc. NC was one of several institutional investors that added to or reduced their stakes in Axsome Therapeutics during the fourth quarter. Other major investors that increased their positions include Wellington Management Group LLP, Invesco Ltd., and Adage Capital Partners GP L.L.C.

  • Franklin Street Advisors Inc. NC acquired the new position in Axsome Therapeutics during the fourth quarter of 2025.

The players

Franklin Street Advisors Inc. NC

An institutional investor that acquired a new position in Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders.

Got photos? Submit your photos here. ›

The takeaway

The investment by Franklin Street Advisors Inc. NC in Axsome Therapeutics reflects growing institutional interest in the company's pipeline of CNS drug candidates, which could signal positive momentum for the stock going forward.